Physician profile
Laura Balmain
NPI 1386642692
$5,907.06
in general payments reported to CMS, 2019-2025
30 companies · $18.12 in 2025
The $18.12 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,034 · 2020: $742 · 2021: $1,225 · 2022: $985 · 2023: $1,032 · 2024: $871 · 2025: $18.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,920.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,097.34 | 2019-2024 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $597.68 | 2019-2024 | Stelara, Simponi Aria, Simponi |
| Pfizer INC. | $587.20 | 2019-2024 | |
| Gilead Sciences, INC. | $543.08 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $462.89 | 2019-2023 | Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $404.77 | 2019-2024 | Entyvio, Eohilia |
| Genzyme Corporation | $239.02 | 2022-2024 | |
| Ardelyx, INC. | $116.22 | 2022-2024 | Ibsrela |
| Celgene Corporation | $89.43 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $79.57 | 2020-2023 | Ocaliva |
| Lilly USA, LLC | $72.12 | 2024 | Omvoh |
| Nestle Healthcare Nutrition INC. | $63.13 | 2021-2023 | |
| Braintree Laboratories, INC. | $56.61 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $54.04 | 2024-2025 | Voquezna |
| Allergan, INC. | $50.05 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $47.82 | 2019 | |
| Merck Sharp & Dohme LLC | $47.35 | 2019-2024 | Dificid |
| Regeneron Healthcare Solutions, INC. | $38.10 | 2023 | Dupixent |
| Medtronic, INC. | $37.77 | 2021-2023 | Endoflip |
| Redhill Biopharma INC. | $36.21 | 2021 | |
| Ironwood Pharmaceuticals, INC | $34.92 | 2019 | |
| Amgen INC. | $29.33 | 2020-2021 | |
| Myriad Genetic Laboratories, INC. | $21.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.93 | 2023 | |
| Madrigal Pharmaceuticals | $19.62 | 2024 | Resmetirom |
| Evoke Pharma, INC. | $15.68 | 2021 | |
| Shionogi INC | $13.75 | 2020 | |
| Axonics, INC. | $13.49 | 2020 | |
| Ucb, INC. | $12.54 | 2020 | |
| Sirtex Medical INC | $6.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Balmain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.